K 13
Alternative Names: K 13; K13 peptide; SY 007Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Primary Peptides
- Developer Primary Peptides; Yabao Pharmaceutical Group
- Class Antithrombotics; Neuroprotectants; Peptides; Vascular disorder therapies
- Mechanism of Action PTEN inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Stroke(In volunteers) in China (IV, Injection)
- 10 Jan 2023 K 13 is still in phase I trials for Stroke (In volunteers) in China (NCT04891913) (Primary Peptides pipeline, January 2023)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Stroke(In volunteers) in China (IV, Injection)